Uniqure (QURE) Receives Daily News Impact Score of 0.12
Media stories about Uniqure (NASDAQ:QURE) have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Uniqure earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.2399628426067 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Uniqure NV (QURE) Short Interest Update (americanbankingnews.com)
- uniQure to Participate in Multiple Conferences in March – GlobeNewswire (press release) (globenewswire.com)
- 66,270 Shares in Uniqure NV (QURE) Purchased by Victory Capital Management Inc. (americanbankingnews.com)
- Uniqure (QURE) Cut to Sell at Zacks Investment Research (americanbankingnews.com)
Shares of Uniqure (NASDAQ QURE) opened at $26.59 on Friday. Uniqure has a twelve month low of $4.72 and a twelve month high of $26.75. The stock has a market capitalization of $768.77, a PE ratio of -10.19 and a beta of 0.09. The company has a current ratio of 3.64, a quick ratio of 3.64 and a debt-to-equity ratio of 0.73.
In other Uniqure news, insider Deventer Sander Van sold 5,985 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $18.53, for a total value of $110,902.05. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Maria E. Cantor sold 5,864 shares of the company’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $20.13, for a total value of $118,042.32. The disclosure for this sale can be found here. Insiders have sold 41,510 shares of company stock worth $815,776 in the last quarter. 0.73% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2018/03/03/uniqure-qure-receives-daily-news-impact-score-of-0-12.html.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.